Business Context and Reporting Period
This Form 8-K filing by Krystal Biotech, Inc. (Delaware) was submitted on May 9, 2018, reporting events occurring on May 3, 2018. The Company is an emerging growth company focused on biotechnology, with principal executive offices in Pittsburgh, Pennsylvania.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document is limited to reporting changes in executive and director compensation arrangements.
Material Changes
The Board of Directors, upon recommendation of the Compensation Committee, approved the following compensation adjustments effective June 1, 2018:
- CEO Compensation: Krish S. Krishnan's annual base compensation increased to $470,000. This consists of a $200,000 cash component and a $270,000 equity component (restricted shares valued at $240,000 for vesting calculation purposes). Shares vest monthly over 12 months.
- COO Compensation: Suma M. Krishnan's annual base compensation increased to $367,000. This consists of a $200,000 cash component and a $167,000 equity component (restricted shares). Shares vest monthly over 12 months.
- Performance Bonuses: Potential bonuses established for the fiscal year ending December 31, 2018, capped at 50% of base compensation for the CEO and 35% for the COO. Performance goals are to be set by the end of the second fiscal quarter.
- Director Compensation: New fee structure for non-employee directors (not employed by strategic/institutional investors):
- Annual cash retainer: $37,500.
- Committee Chair fees: Audit ($15,000), Compensation ($10,000), Governance/Nominating ($8,000).
- Committee Member fees: Audit ($7,500), Compensation ($5,000), Governance/Nominating ($4,000).
- Equity grants: Initial grant of 20,000 options (vesting over 3 years) for new directors; annual grant of 7,500 options (vesting over 12 months) for existing directors.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or discuss specific risks or contingencies beyond the standard disclosure of compensation changes. The Board anticipates establishing performance goals for the executive bonuses prior to June 30, 2018.
Investor Verification Checklist
- Verify the closing price of Krystal Biotech Common Stock on June 1, 2018, to calculate the exact number of restricted shares awarded to the CEO and COO.
- Monitor the Company's subsequent filings for the specific performance goals established for the 2018 executive bonuses.
- Review the Company's equity incentive plan to confirm the availability of shares for the new director option grants.
- Confirm the vesting schedule and any potential acceleration clauses related to a change in control for the new director options.